

**بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ**

**قال الله تعالى**

**اقْرَأْ بِاسْمِ رَبِّكَ الَّذِي خَلَقَ (1) خَلَقَ الْإِنْسَانَ مِنْ عَلَقٍ (2) اقْرَأْ وَرَبُّكَ  
الْأَكْرَمُ (3) الَّذِي عَلَّمَ بِالْقَلَمِ (4) عَلَّمَ الْإِنْسَانَ مَا لَمْ يَعْلَمْ (5)**

**صدق الله العظيم**  
**سورة العلق الآيات 1-5**

## **Dedication**

To who taught me how to be a valuable member in the community

My father

To who gave me love and security

My mother

To dear brother and sisters

To my dear husband

## Acknowledgment

First of all I thanks to **.almightly allah** the beneficent, and merciful for giving me the strength, and health to accomplish this work.

I express my deepst gratitude to my supervisor **Dr . wafa Ibrahim Elhag** for valuable comments, critical advices, continous support and close supervision.

Faithfully, Iwoud like to thank all people who contributed much to the performance of this study and make it possible and visible.

The assistant and help of all the members of the Alsudi Hospital –Kassala, was highly appreciated.

To those who helped me to complete this research to all my colleagues in Sudan University.

## **ABSTRACT**

This was descriptive- cross sectional study, which was conducted to determine the frequency of human immunodeficiency virus (HIV) antibodies among pregnant ladies attending a prenatal clinic in Alsuadi Hospital- Kassala State during the period from April to September 2012 and to detect relation between presence of anti HIV antibody and certain risk factors e.g. duration of pregnancy gravidity, Educational status and history of surgical operation.

Ninety sera from pregnant ladies were collected and investigated by 4th generation ELISA technique.

The pregnant ladies examined were age range from (15-37) years with a mean of 26 year.

None of population under study were seropositive for HIV (0%) , 81.1% were in Third trimesters, ( 78.8%) multi gravidia, 55.5% were educated, and (16.7%) had past history of surgical operation.

هذه دراسة وصفية عرضية أجريت لمعرفة نسبة تردد الاجسام المضادة لفيروس نقص المناعة المكتسبة وسط السيدات الحوامل بالمستشفى السعودي بكسلا في الفترة من ابريل الى سبتمبر 2012 وكذلك مقارنة بين وجود الاجسام المضادة لفيروس نقص المناعة المكتسبة. وعوامل اخري مثل المستوى التعليمي اجراء العمليات الجراحية فترة الحمل . وعدد مرات الحمل .

. تسعون من السيدات الحوامل تم فحصهم بعد اخذ عينة السيرم باستخدام تقنية الاليزا .معظم السيدات الحوامل تتراوح اعمارهم في المدي بين 15-37 سنة بمتوسط 26 سنة . لم تثبت هذه الدراسة وجود اي اجسام مضادة لفيروس نقص المناعة المكتسبة وسط السيدات الحوامل .كانت اغلب النساء الحوامل 73% حوامل في الثلث الثالث و 71% (متعدد الحمل و 55.5% متعلمات و 16.7% اجريت لهم عمليات جراحية في السابق

## TABLE OF CONTENT

Pag e no	Subject
I	الآية
II	Dedication
III	Acknowledgments
IV	Abstract
V	الخلاصة
VI	Table of Content
IX	List of figures
IX	List of tables
X	List of abbreviations
	<b>CHAPTER ONE: INTRODUCTION</b>
1	1.1 Introduction
3	1.2 Objectives
3	1.2.1 General Objective
3	1.2.2 Specific Objectives
	<b>CHAPTER TOW: LITERATURE REVIEW</b>
4	2. Literature review
4	2.1 Epidimology of HIV
4	2.2 History of HIV
4	2.2.1 Origins
5	2.2.2 Discovery
5	2.3 Classification of HIV
6	2.3.1 Types of HIV
6	2.3.1.1 HIV-1
6	2.3.1.1.1 HIV-1 group M
7	2.3.1.1.2 HIV-1 group N
8	2.3.1.1.3 HIV-1 group O

8	2.3.1.1.4 HIV-1group P
8	2.3.1.2 HIV-2
9	2.4 General features of HIV
9	2.4.1Structures and Genome
11	2.4.2.HIV tropism
13	2.4.3 Replication cycle
13	2.4.3.1Cell entry
14	2.4.3.2 Replication and transcription
16	2.4.3.3 Assembly and release
16	2.4.4Genetic variability
17	2.5Tranmission of HIV
17	2.5.1Sexual intercourse
17	2.5.2 Blood products
18	2.5.3 Mother-to-child
18	2.6 Signs and symptoms
18	2.6.1Primary infection
19	2.6.2 Latent infection
19	2.6.3Chronic infection
20	2.7 WHO Disease Staging System for HIV Infection
21	2.8 HIV and pregnancy
22	2.9 Laboratory diagnosis
22	2.9.1 Antibody tests
23	2.9.1.1 Window period
23	2.9.1.2 ELISA test
24	2.9.1.3 Western Blot
24	2.9.1.4 Rapid or point-of-tests
25	2.9.2 Antigen test
25	2.9.3 Nucleic Acid-based-tests(NAT)
26	2.9.3.1 RT PCR
26	2.9.3.2 Quantiplex DNA
27	2.10 Management

28	2.11 HIV prevention strategies
28	2.11.1 pharmaceutical strategies
28	2.11.2 Social strategies
29	2.12 Background studies
	<b>CHAPTER THREE: MATERIALS AND METHODS</b>
30	3. Materials and methods
30	3.1 Study design
30	3.2 Study area
30	3.3 study population
30	3.4 Inclusion criteria
30	3.5 Exclusion criteria
30	3.6 Sample size
30	3.7 Data collection
30	3.8 Ethical clearance
31	3.9 Experimental work
31	3.9.1 Specimen collection
31	3.9.2 Preservation and storage of the specimens
31	3.9.3 Specimen processing
31	3.9.3.1 ELISA for Anti HIV1-2-0
31	3.9.3.2 Assay procedure
33	3.9.3.3 Interpretation of the results and quality control
34	3.9.3.3.1 Calculation of cut-off
34	3.9.3.3.2 Quality control range
35	3.9.3.3.3 Interpretation of results
35	3.9.3.3.3.1 Negative result
35	3.9.3.3.3.2 Positive result
35	3.9.3.3.3.3 Borderline result
	<b>CHAPTER FOUR: RESULTS</b>
36	4. Results
	<b>CHAPTER FIVE: DISCUSSION</b>
39	5.1 Discussion
40	5.2 Conclusion
40	5.3 Recommendations
41	REFERENCES
50	APPENDICES



### List of figures

Page no	Figure
11	1 . Structure of Human immunodeficiency virus

### List of Tables

Page no	Table
37	1 . Distribution of study population according to their age range
37	2. Distribution of study population according to their Gravidity
38	3. Distribution of study population according to their duration of trimester
38	4. Distribution of study population according to their Education Status

## List of abbreviations

FDC	Follicular dendritic cells
WHO	World health organization
LAV	Lymphadenopathy-associated virus
ART	Antiretroviral treatment
cDNA	Complementary deoxy ribonucleic acid
SNAP	Sudanese National AID Program
CD8-1	cluster of differentiation 8-1
DC-SIGN	Dendritic cell-specific intracellular adhesion molecule grabbing non-integrin
E	Envelop
ELISA	Enzyme-linked immunosorbent assay
KS	Kaposi's sarcoma
LTR	Long terminal repeat
HIV	Human immunodeficiency virus
HRP	Horse Redish peroxidase
IFA	Immunofluorescence assay
OD	optical density
PCR	polymerase chain reaction
RIBA	Recombinant immoblot assay
RNA	Ribonucleic acid
RT-PCR	Reverse transcriptase-PCR
NARTIs	Nucleoside analogue reverse transcriptase inhibitors
NNRTIs	Non –nucleoside reverse transcriptase inhibitors
US	United States
AIDS	Acquired Immunodeficiency Syndrome